surmount trials tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial ESC 2025: post-hoc SURMOUNT-5 data

With med sync, patients can avoid multiple trips to the pharmacy and reduce the risk of missed doses

Summer brings heat risk, winter brings freezing risk, and the transitions between seasons bring the less obvious risk of assuming your home temperature is stable when it may not be

Many people stay on this dose for a few weeks to allow their body to adjust to the medication

Remember to follow the manufacturer's instructions, as the process may vary depending on the peptide

The 28.7% weight loss and 82% liver fat reduction could justify this designation, particularly for MASLD, which currently has limited treatment options